Claudia Battisti

Dr. Claudia Battisti


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
FDFrancesco Dondi
Francesco Dondi
AMAlberto Miceli
Alberto Miceli
GRGuido Rovera
Guido Rovera
VFVanessa Feudo
Vanessa Feudo
CBClaudia Battisti
Claudia Battisti
GSGiulia Santo
Giulia Santo
Introduction: The term theragnostic refers to the combination of a predictive imaging biomarker with a therapeutic agent. The promising application of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals in the imaging and treatment of prostate cancer (PCa) patients opens the way to investigate a possible role of PSMA-based radiopharmaceuticals in cancers beyond the prostate. Therefore, the aim of this review was to evaluate the role of 177Lu-PSMA radioligand therapy (RLT) in malignancies other than prostate cancer by evaluating preclinical, clinical studies, and ongoing clinical trials. Methods: An extensive literature search was performed in three different databases using different combinations of the following terms: “Lu-PSMA”, “177Lu-PSMA”, “preclinical”, “mouse”, “salivary gland cancer”, “breast cancer”, “glioblastoma”, “solid tumour”, “renal cell carcinoma”, “HCC”, “thyroid”, “salivary”, “radioligand therapy”, and “lutetium-177”. The search had no beginning date limit and was updated to April 2024. Only articles written in English were included in this review. Results: A total of four preclinical studies were selected (breast cancer model n = 3/4). PSMA-RLT significantly reduced cell viability and had anti-angiogenic effects, especially under hypoxic conditions, which increase PSMA binding and uptake. Considering the clinical studies (n = 8), the complexity of evaluating PSMA-RLT in cancers other than prostate cancer was clearly revealed, since in most of the presented cases a sufficient tumour radiation dose was not achieved. However, encouraging results can be found in some types of diseases, such as thyroid cancer. Some clinical trials are still ongoing, and results from prospective larger cohorts of patients are awaited. Conclusions: The need for larger patient cohorts and more RLT cycles administered underscores the need for further comprehensive studies. Given the very preliminary results of both preclinical and clinical studies, ongoing clinical trials in the near future may provide stronger evidence of both the safety and therapeutic efficacy of PSMA-RLT in malignancies other than prostate cancer.

2 September 2025 in Life
Verified
Journal Article
Open access
PDF file
DRDino Rubini
Dino Rubini
VNValerio Nardone
Valerio Nardone
CACorinna Altini
Corinna Altini
CBClaudia Battisti
Claudia Battisti
CFCristina Ferrari
Cristina Ferrari
SCSalvatore Cappabianca
Salvatore Cappabianca
Modern external beam radiotherapy (EBRT) on lung cancer improved dose distribution thanks to advanced dose calculation algorithms, but side effects and relapses can occur in any case onset. Differential diagnosis of relapses and side effects is difficult, and when computed tomography (CT) is uncertain 18-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) can support the diagnosis, even if it can also be difficult to construe. The aim of this retrospective analysis was to evaluate 18F-FDG PET/CT qualitative patterns and semiquantitative parameters, both automatic and preceded by physicians, in interpreting lung lesions in the radiotherapy (RT) lung irradiation field. In total, 94 patients (pts) submitted to EBRT (3 months before) for stage II lung cancer were included (74 men, 20 women, mean age of 68 years old, range of 49–84 years old). CT scans were performed on pts, which showed lung lesions in the RT field. 18F-FDG-PET/CT scans were analyzed qualitatively as negative or positive, and the presence of the lung area with a high 18F-FDG uptake pattern was distinguished as the following: focal/wide, deep/shade, or homogeneous/inhomogeneous. Furthermore, the following semiquantitative parameters were collected: gSUVmax (global standardized uptake value max), MTV (tumor metabolic volume), metabolic spatial distribution (MSD) = proximal SUVmax/distal SUVmax, and intratumoral difference in spatial distribution (IDSD%) = [distal SUVmax/proximal SUVmax] × 100. 18F-FDG PET/CT was related to the pts’ outcome (biopsy and/or clinical–instrumental follow-up): positive for lung relapse, negative if the lesions were phlogistic. The following diagnostic performance parameters of 18F-FDG PET/CT were calculated: sensitivity (Sens), specificity (Spec), diagnostic accuracy (DA), positive predictive value (PPV), and negative predictive value (NPV). Qualitative variables were compared by Chi-squared test, while for semiquantitative parameters Student’s t-test was applied; p < 0.05 was considered statistically significant. Statistics tests were performed with MedCalc V.22.018 ©2024. In 76/94 (80.8%) pts, 18F-FDG uptake was higher compared to the background; in 18/94 (19.2%) no high 18F-FDG uptake areas were detected. Outcome was positive for lung relapse in 49/94 pts, while negative in 45/94, with disease prevalence of 52.13% (95%CI = 41.57–62.54%). In the 18/94 pts without high 18F-FDG uptake, the outcome was negative for lung relapse. In 49/76 pts with higher 18F-FDG uptake, the outcome confirmed the presence of relapse, while in 27/76 the lesion was phlogistic. Results about the Sens, Spec, DA, PPV, and NPV (95%CI) were, respectively: 100% (92.75–100%), 40% (25.7–55.67%), 71.28% (61.02–80.14%), 64.47% (58.84–69.73%), and 100% (81.47–100%). Chi-square test showed significant statistical difference between the positive and negative outcome for patterns focal/wide (p = 0.02) and deep/shade (p < 0.00001). A total of 35/49 (71.4%) pts with lung relapse had a focal lesion and 15/27 (55.6%) with phlogosis had a wide pattern. A total of 34/49 (69.4%) pts with lung relapse had a deep pattern and 25/27 (92.6%) with lung phlogosis had the shade one. Significant difference was observed in evaluating the three patterns (p = 0.00007), with prevalence of “focal/deep/homogeneous” patterns in lung relapse and “wide/shade/inhomogeneous” in phlogosis. gSUVmax, MTV, MSD, and IDSD% were in the following order: in the 76 pts, 5.63 (1.4–24.7), 42.49 (4.94–193), 3.61 (1–5.54), and 70.7% (18–100%); in the 49/76 true positive pts, 6.93 (1.5–24.7), 35.28 (4.94–85.99), 3.30 (1.05–5.54), and (18–95%); in the 27/76 false positive pts, 3.27 (1.4–19.2), 38.37 (4.94–193), 1.57 (1–2.13), and 78.6% (4.7–100%). The difference was statistically significant only for MSD (t = 2.779; p = 0.0069) and IDSD% (t = 2.769; p = 0.0071). 18F-FDG-PET/CT confirms its high sensitivity and NPV in evaluating lung lesions after RT. To improve physician confidence in interpreting lung 18F-FDG uptake without further support, MSD and IDSD% could be considered. Heterogeneity of lung lesions, especially in radiotreated tissue, can be turned from a drawback to a resource and analyzed for differentiating relapses from EBRT side effects. Considering the calculation of semiquantitative parameters that require “human intelligence”, even if slightly more time-consuming, can improve the nuclear physician’s confidence in interpreting 18F-FDG PET/CT images.

28 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CBClaudia Battisti
Claudia Battisti
DRDino Rubini
Dino Rubini
ANAnna Giulia Nappi
Anna Giulia Nappi
CFCristina Ferrari
Cristina Ferrari
GRGiuseppe Rubini
Giuseppe Rubini
Background: NUT carcinoma (NC) is a rare and highly aggressive NUTM1-rearranged malignancy characterized by rapid progression, frequent metastatic dissemination, and poor clinical outcomes. Evidence regarding the role of [18F]FDG PET/CT remains limited and is largely based on isolated case reports and small series. We describe serial [18F]FDG PET/CT findings in three pediatric and young-adult patients with NC and place these observations in the context of a structured narrative review of the available PET literature. Case Series and Methods: Three patients with histologically confirmed NC arising from the anterior chest wall, head and neck region, and mediastinal region underwent [18F]FDG PET/CT at baseline and during treatment or follow-up. All primary tumors were FDG-avid, although metabolic activity, disease distribution, treatment-related imaging changes, and clinical outcomes were markedly heterogeneous. Baseline PET/CT depicted FDG-avid primary, nodal, and distant disease; in one patient, skeletal lesions were identified without corresponding CT abnormalities, while in another, an additional skeletal PET finding prompted whole-body MRI evaluation. Serial PET/CT documented longitudinal changes in FDG uptake and disease distribution, without assigning formal metabolic response categories. The patient with localized disease remained alive and in complete clinical remission at 30 months, whereas the two patients with metastatic disease died 11 and 12 months after diagnosis, respectively. Baseline MTV and TLG showed substantial inter-patient variability and were explored only as descriptive quantitative measures of metabolically active disease burden. Conclusions: These observations illustrate the potential complementary contribution of [18F]FDG PET/CT to multimodality imaging in NUT carcinoma, particularly for whole-body disease depiction and assessment of longitudinal metabolic changes. MTV and TLG should be regarded as exploratory, method-dependent descriptive measures and are not validated biomarkers in NC. Larger multicenter studies using standardized acquisition, analysis, and longitudinal interpretation methods are required.